Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Avedro Financing Highlights New Ophthalmology Market

This article was originally published in Start Up

Executive Summary

In early July, ophthalmology start-up Avedro closed a $25 million Series C round. In a refractive surgery market where, apart from laser cataract surgery, there hasn't been much new to speak of in years, Avedro has a potentially disruptive technology, although the company plans not to disrupt as much as to grow the market.

You may also be interested in...

Medtech Start-Up Financing Strategies: Where’s The Money?

Despite the dire headlines, VCs are still investing in medtech start-ups, although the deals are becoming fewer and later stage. Start-ups looking for funding have to be more creative and look beyond traditional sources of funding, according to a discussion by six European venture capitalists speaking at the IN3 meeting in Dublin in April 2013.

Ophthalmology Community Focuses on Laser Cataract Technology

Among new technologies discussed at three major ophthalmology conferences this fall, it was the emerging field of laser cataract surgery that generated the greatest interest among attendees, although the first system is just now being launched commercially and there are many unanswered questions regarding the economics of this promising technology and how it will be adopted.

ASCRS: A Look Ahead in Eye Surgery

At this year's American Society of Cataract and Refractive Surgery symposium, enthusiasm over technological advances in nearly every product segment, including presbyopia-correcting IOLs and cataract surgeries, was dampened by the reality of the softening demand for laser vision correction.


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts